Wuhan Hvsen Biotechnology Co Ltd
300871
Company Profile
Business description
Wuhan Hvsen Biotechnology Co Ltd is engaged in research and development, production and sales of veterinary drugs (including chemical drug preparations, raw materials, and Chinese medicine preparations), feed and additives. It produces tylvalosin raw material, various tylvalosin preparations, florfenicol preparations and other macrolides products.
Contact
218 Zhangbai Road
Dongxihu District
Hubei Province
Wuhan430042
CHNT: +86 2783235399
Sector
Healthcare
Stock type
Defensive
Industry
Biotechnology
Fiscal Year End
31 December 2026
Employees
1,028
Stocks News & Analysis
stocks
Finding yield on the ASX
The ASX, known for its yield appeal is at its lowest level in 20 years. Here’s why, and what investors should do.
stocks
ExxonMobil earnings: Continued execution, on track for 2030 targets
We’ve raised our fair value estimate of Exxon stock.
stocks
Disney earnings: No big surprises in solid results
Growth in areas critical to the firm’s future.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 9,149.30 | 6.90 | -0.08% |
| CAC 40 | 8,150.11 | 31.06 | -0.38% |
| DAX 40 | 24,751.91 | 45.61 | -0.18% |
| Dow JONES (US) | 49,400.46 | 7.20 | -0.01% |
| FTSE 100 | 10,288.82 | 52.74 | -0.51% |
| HKSE | 26,834.77 | 59.20 | 0.22% |
| NASDAQ | 23,329.90 | 262.21 | -1.11% |
| Nikkei 225 | 54,720.66 | 2,065.48 | 3.92% |
| NZX 50 Index | 13,421.52 | 9.08 | 0.07% |
| S&P 500 | 6,937.69 | 38.75 | -0.56% |
| S&P/ASX 200 | 8,857.10 | 9.20 | -0.10% |
| SSE Composite Index | 4,067.74 | 51.99 | 1.29% |